India, Oct. 14 -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (KYKOY), announced the publication of three-year real-world findings comparing burosumab with oral phosphate and active vitamin D (Pi/D) in adults with X-linked hypophosphatemia (XLH). The interim analysis of the XLH Disease Monitoring Program was published in the Journal of Bone and Mineral Research.
The analysis included 109 adults with XLH, comprising 54 treated with burosumab and 55 receiving Pi/D. Researchers assessed serum phosphate levels and patient-reported pain, stiffness and physical function at years one and three.
XLH is a rare, lifelong genetic disorder caused by excessive phosphate loss, which can weaken bones and muscles and lead to ske...